Dynavax Technologies Corporation news

   Watch this stock
Showing stories 1 - 1 of about 1   

Articles published

DVAX 26.43 +1.08 (4.26%)
price chart
Andrew Gengos out, John Walker in as Neuraltus CEO
Andrew Gengos, who led Neuraltus Pharmaceuticals Inc. into a Phase II trial of its experimental treatment for Lou Gehrig's disease, has left the company.